Astex Therapeutics Limited
Registered name: ASTEX THERAPEUTICS LIMITED
Part of Otsuka America Inc groupAstex Therapeutics Limited made £404m revenue and £283m profit in the year to 31 Dec 2025. read from filing text
Astex Therapeutics Limited’s revenue grew 46% to £404m in the year to 31 Dec 2025, with £283m profit and 183 employees. The company is classified under “research and experimental development on biotechnology” and is based in Cambridge; we hold 4 years of its filed accounts.
- Status
- Active
- Location
- Cambridge, East of England
- Age
- 27 yrs · since 1999
- Type
- Private Limited Company
Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2022 | 31 Dec 2023 | 31 Dec 2024 | 31 Dec 2025 |
|---|---|---|---|---|
| Disclosure | Full P&L | Full P&L | Full P&L | Full P&Lread from filing text |
| Profit & loss | ||||
| Revenue (turnover) | £117m | £202m | £277m | £404m |
| Cost of sales | — | — | £54.1m | £54.6m |
| Operating profit | £69.1m | £139m | £218m | £340m |
| Profit before tax | £73.3m | £137m | £219m | £331m |
| Profit after tax | £65.7m | £122m | £189m | £283m |
| Profit (best available) | £65.7m | £122m | £189m | £283m |
| Employees (average) | 157 | 166 | 173 | 183 |
| Ratios | ||||
| Profit margin | 56.1% | 60.3% | 68.4% | 70.2% |
| Revenue per employee | £746k | £1.2m | £1.6m | £2.2m |
| Profit per employee | £419k | £735k | £1.1m | £1.5m |
| Growth (year on year) | ||||
| Revenue growth | — | ▲72.8% | ▲36.7% | ▲45.9% |
| Profit growth | — | ▲85.6% | ▲55.1% | ▲49.8% |
| Headcount growth | — | ▲5.7% | ▲4.2% | ▲5.8% |
| Balance sheet — indirect signals, not revenue | ||||
| Cash at bank | £38.1m | £75.8m | £114m | £53.1m |
| Net assets | £89m | £136m | £200m | £164m |
| Fixed assets | £22m | £21.5m | — | — |
| Current assets | £72.3m | £139m | £208m | £178m |
| Debtors | £31.1m | £58m | — | — |
| Deferred income | — | £5.3m | — | — |
| Source | Accounts · bulk data Apr 2024 | Accounts · bulk data Apr 2024 | Accounts · bulk data Mar 2025 | FullAccounts · bulk data Feb 2026 |
How the business works
- Profit margin
- 70.2%
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £2.2m
- Revenue ÷ average employees.
- Profit per employee
- £1.5m
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- ▼18%
- Now £164m
- Cash at bank
- ▼53%
- Now £53.1m
- Headcount
- ▲6%
- Now 183
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Group structure
Ownership chain
- Otsuka America Inc (registered outside the UK register)ultimate parent75–100%
- Astex Therapeutics Limitedthis company
Bands show the share of ownership each company holds in the one below it.
From the Persons with Significant Control register (corporate controllers only).
Sources
Latest figures from FullAccounts for the year to 31 Dec 2025 (profit £283m), from the Companies House accounts bulk data published Feb 2026. Spotted an error? Request a correction.
Updated from Companies House on 11 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.